GlaxoSmithKline plc (GSK) PT Set at GBX 1,450 by Morgan Stanley
GlaxoSmithKline plc (LON:GSK) has been assigned a GBX 1,450 ($19.07) price objective by stock analysts at Morgan Stanley in a research report issued to clients and investors on Monday. The brokerage presently has a “sell” rating on the stock. Morgan Stanley’s price target indicates a potential upside of 7.58% from the company’s previous close.
Several other analysts have also issued reports on the stock. Deutsche Bank AG set a GBX 1,610 ($21.18) price target on shares of GlaxoSmithKline plc and gave the company a “neutral” rating in a research report on Friday, October 27th. Goldman Sachs Group, Inc. (The) set a GBX 1,900 ($24.99) price target on shares of GlaxoSmithKline plc and gave the company a “buy” rating in a research report on Wednesday, July 26th. Jefferies Group LLC reiterated a “buy” rating and set a GBX 1,900 ($24.99) target price on shares of GlaxoSmithKline plc in a report on Thursday, July 13th. Investec reiterated an “under review” rating on shares of GlaxoSmithKline plc in a report on Friday, October 27th. Finally, Barclays PLC reiterated an “equal weight” rating and set a GBX 1,450 ($19.07) target price on shares of GlaxoSmithKline plc in a report on Friday, October 27th. Three analysts have rated the stock with a sell rating, twelve have assigned a hold rating and six have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of GBX 1,591.75 ($20.94).
Shares of GlaxoSmithKline plc (GSK) opened at GBX 1,347.90 ($17.73) on Monday. GlaxoSmithKline plc has a 1 year low of GBX 1,336 ($17.57) and a 1 year high of GBX 1,724.50 ($22.68).
GlaxoSmithKline plc (LON:GSK) last posted its quarterly earnings results on Wednesday, October 25th. The company reported GBX 32.50 ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of GBX 31.80 ($0.42) by GBX 0.70 ($0.01). GlaxoSmithKline plc had a negative net margin of 1.17% and a negative return on equity of 57.19%. The business had revenue of GBX 784.30 billion during the quarter.
WARNING: This story was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.thecerbatgem.com/2017/11/08/glaxosmithkline-plc-gsk-pt-set-at-gbx-1450-by-morgan-stanley.html.
In other GlaxoSmithKline plc news, insider Urs Rohner purchased 473 shares of the company’s stock in a transaction dated Wednesday, October 25th. The shares were acquired at an average price of GBX 1,518 ($19.97) per share, for a total transaction of £7,180.14 ($9,443.82). Also, insider Simon Dingemans purchased 1,076 shares of the company’s stock in a transaction dated Thursday, October 12th. The shares were acquired at an average price of GBX 1,527 ($20.08) per share, for a total transaction of £16,430.52 ($21,610.57). Insiders purchased 1,566 shares of company stock worth $2,386,736 in the last 90 days.
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Stock Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related stocks with our FREE daily email newsletter.